[Weekend Money] This Pharmaceutical Company Has the Highest Expectations for Technology Transfer This Year
"Hanmi Pharmaceutical, Strong Advantage in Obesity Treatment Portfolio"
Domestic pharmaceutical companies can earn revenue by developing their own new drugs, but they also generate profits through "technology transfer," handing over new drug candidates or technical know-how to global big pharma companies. Hana Securities selected Hanmi Pharmaceutical as the pharmaceutical company with the highest expectations for technology transfer this year.
Kim Seona, a researcher at Hana Securities, analyzed that Hanmi Pharmaceutical has a strong advantage in technology transfer within its obesity treatment line. She explained, "Most big pharma companies have now secured obesity treatment compounds, and RNAi-based candidates have demonstrated remarkable results by reducing only visceral fat while preserving muscle, so development strategies beyond just the amount of weight loss have become necessary." She further emphasized, "Although the movement among big pharma to introduce new obesity treatment compounds has noticeably declined, Hanmi Pharmaceutical's positioning in the obesity treatment segment remains significant."
Hanmi Pharmaceutical succeeded in developing Efeglenatide, the first domestic new drug for obesity, and is scheduled to launch it in the fourth quarter of this year. Researcher Kim evaluated, "Although Wegovy and Mounjaro currently dominate the market, Hanmi Pharmaceutical's product is optimized for Asians and has fewer side effects such as nausea, which will allow it to rapidly gain market share."
Other pipelines with high potential for technology transfer include HM15275 (a triple agonist) and HM17321 (muscle growth agent). HM15275 is currently in Phase 2 clinical trials, and patient enrollment was completed in early April, making it likely that the clinical trial will be completed in the first half of next year. For HM17321, the single ascending dose (SAD) trial was completed in the United States, and a multiple ascending dose (MAD) trial is set to begin this month, with results from the SAD trial expected to be announced around August. Researcher Kim noted, "Unless announced otherwise, the R&D results for these pipelines are expected to be presented at academic conferences such as Obesity Week and the International Society for Pediatric and Adolescent Diabetes (ISPAD) in November."
Researcher Kim pointed out that MSD, which has maintained a long-standing partnership with Hanmi Pharmaceutical, has shown interest in metabolic diseases by developing obesity and metabolic dysfunction-associated steatohepatitis (MASH) treatments, but has not developed or succeeded with an obesity treatment to date. She also noted that Roche, in March last year, introduced an amylin analogue from Zealand Pharma to build compounds targeting key obesity treatment targets like those of Eli Lilly and Novo Nordisk, but still lacks triple agonist and muscle growth agent pipelines.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Researcher Kim added, "Hanmi Pharmaceutical's annual guidance of at least one technology transfer is possible because numerous partners are showing strong interest, and contract negotiations have progressed to the point where at least the term sheet has been substantially finalized."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.